These data together with earlier studies in skeletal muscle and liver highly suggest that pharmacological disruption of ILK interactions would have metabolic beneficial effects on improving insulin sensitivity and provide promising therapeutic potential for diabetes and metabolic disorders. This evidence concerns the gene ILK and metabolic disease.